



DRUG REGULATORY AUTHORITY OF PAKISTAN

Division of Quality Assurance and Laboratory Testing

RAPID ALERT

DRAP ALERT No: N° I/S/07-26-39

SPURIOUS AND UNREGISTERED ONCOLOGY PRODUCTS IDENTIFIED BY THE DRUG TESTING LABORATORY, SINDH (KARACHI)

Date: 29th July, 2026

Target Audience:

- National Regulatory Field Force of DRAP and Provincial Drug Control Departments.
- Healthcare Professionals (Oncologists, Hematologists, Pharmacists & Nurses).
- Hospitals and Oncology Treatment Centres.
- General Public.

Problem Statement:

The Drug Testing Laboratory Sindh, Karachi, under the Provincial Government Analyst, has reported the following oncology drug products were declared **Spurious/unregistered**, as laboratory identification confirmed the absence of the declared active pharmaceutical ingredient, as defined under Section 3(z)(b)(i) read with Section 23(1)(a)(i) & (vii) of the Drugs Act, 1976.

S#	Product	Batch No.	Manufacturer	Identification Result	Classification
1.	Leukeran-2mg Tablet	512900	Excella GmbH & Co. KG, Feucht, Germany	Chlorambucil (confirmed)	Unregistered
2.	Sarafenib/Sorafenib-200mg Tablet (Soraclog)	GST56925-C	Globela Pharma (Pvt) Ltd, Surat, India	Sorafenib Tosylate — Not Identified	Spurious & Unregistered
3.	Arimidex-1mg Tablet	B2417	Haupt Pharma Münster GmbH, Germany	Anastrozol (confirmed)	Unregistered
4.	Lenvaxen 4 Capsule	26ALV04004	Everest Pharmaceutical Ltd, Narayanganj, Bangladesh	Lenvatinib Mesylate (confirmed)	Unregistered



DRAP, Islamabad

+ 92 051 9255969

gsms@dra.gov.pk



DRUG REGULATORY AUTHORITY OF PAKISTAN

Division of Quality Assurance and Laboratory Testing

5.	Cyclophosphamide-50mg Tablet	OT0470	Kwality Pharmaceutical Ltd, Kangra, India	Cyclophosphamide not Identified	Spurious & Unregistered
6.	Gefimied-250mg Tablet	25GST016	Globela Pharma (Pvt) Ltd, Surat, India	Gefitinib (confirmed)	Unregistered
7.	Lenvatinib-10mg Capsule (Lenvalieva)	C25LN03B3	Allieva Pharma (Pvt) Ltd, Baddi, Himachal Pradesh, India	Lenvatinib Mesylate (confirmed)	Unregistered
8.	Lenalidomide-10mg Capsule	OC0090	Kwality Pharmaceutical Ltd, Kangra, India	Lenalidomide (confirmed)	Unregistered
9.	Nintedanib Soft Gelatin Capsule (Nindanib 150)	24250052	Glenmark Pharmaceuticals Ltd, Daman, India	Nintedanib Ethanesulfonate (confirmed)	Unregistered

Risk Statement:

These are high-value oncology therapeutics (chemotherapy, targeted kinase inhibitors, and hormonal cancer agents) used for the treatment of leukaemia, breast cancer, hepatocellular carcinoma, renal cell carcinoma, multiple myeloma, and related malignancies. Unregistered products have bypassed DRAP's quality, safety, and efficacy evaluation and therefore carry unverified risk. In the products declared spurious, laboratory testing found the stated active ingredient was not identified, meaning the product may deliver no therapeutic effect at all.

Use of these products in cancer patients by an already immunocompromised and vulnerable population may result in treatment failure, disease progression, and potentially life-threatening outcomes.

Action Initiated: -

The Regulatory Field Force of DRAP and Provincial Drug Control Departments has been directed to conduct surveillance activities throughout the supply chain to confiscate the falsified products.

Advice for Healthcare Professionals: -

DRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events





DRUG REGULATORY AUTHORITY OF PAKISTAN

Division of Quality Assurance and Laboratory Testing

or quality problems experienced with the use of these products should be reported to National or Provincial pharmacovigilance centers using [Adverse Event Reporting Form](#) or online through this [link](#). Further information on reporting problems to DRAP is available on this [link](#).

Advice for Consumers:

Consumers should not use these products and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre. All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.



Drug Regulatory Authority of Pakistan

محفوظ، موثر اور معیاری اشیائے علاج



DRAP, Islamabad

+ 92 051 9255969

gsms@dra.gov.pk